Impact of Gastroesophageal Reflux and Aspiration on Airway Inflammation and Microbiome in Children With Chronic Cough
| Status: | Completed |
|---|---|
| Conditions: | Gastroesophageal Reflux Disease , Infectious Disease |
| Therapuetic Areas: | Gastroenterology, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any - 24 |
| Updated: | 1/31/2019 |
| Start Date: | August 5, 2014 |
| End Date: | December 12, 2018 |
Using an active cohort of children in whom Airway and gastrointestinal endoscopy will be
performed, investigators will conduct a chart review to obtain relevant clinical data and the
investigators will use an aliquot of airway sample obtained during the clinically indicated
bronchoscopy for microbiome analysis. A case-control study design will be used to study
whether subjects with CC with GER have a distinct lung microbiome and increased inflammation
as compared with subjects with CC without GER and to determine whether the microbiome and
degree of inflammation is related to the type of GER (acidic versus nonacidic).
performed, investigators will conduct a chart review to obtain relevant clinical data and the
investigators will use an aliquot of airway sample obtained during the clinically indicated
bronchoscopy for microbiome analysis. A case-control study design will be used to study
whether subjects with CC with GER have a distinct lung microbiome and increased inflammation
as compared with subjects with CC without GER and to determine whether the microbiome and
degree of inflammation is related to the type of GER (acidic versus nonacidic).
Inclusion Criteria:
- Children (Age 0 - 24 years) referred to the NYU Pediatric AeroDigestive Center to
evaluate for CC (>4weeks).
Exclusion Criteria:
- Antibiotic or steroids (inhaled or systemic) use within the prior one-week. Rationale:
Antibacterial drugs and immune-modulators are confounders that may impact the
microbiome and inflammation. While longer period free of Antibacterial drugs and
immune-modulators would be desired, it would be unethical and it is not the usual
standard of care to withdraw treatment for longer periods of time.
- Interstitial Lung Disease or pneumonia on X-ray
- Cystic fibrosis
- Primary ciliary dyskinesia
- Immunodeficiency syndromes
- Major airway abnormalities
- Proton pump inhibitor/H2-receptor antagonist therapy within the prior 2 weeks
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Principal Investigator: Mikhail Kazachkov, MD
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials
